A Phase 2 interventional study of EN3835 and Placebo in Adhesive Capsulitis and Frozen Shoulder, sponsored by Endo Pharmaceuticals. Completed at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Bursitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Bursitis · United States.
Among the 45 studies in Bursitis with a site in United States, this one is the 11th largest by enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2020, is one of 6 in phase 2, and was the 35th registered.
383 studies on the registry are indexed under Bursitis; 111 are open to participants now.
Browse Bursitis studies →4 of the 45 studies in Bursitis with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 40+ · Women only
Massachusetts General Hospital · Sites in United States
Ages 18+ · Healthy volunteers
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 64 Bursitis studies recruiting now, 17 (27%) set no upper age limit and 40 (63%) stop at 75 or younger; none take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 5 · Phase 4 8
First in 1997; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 198 is above the median of 44 across 346 interventional studies indexed under Bursitis.
Median enrollment 40 across the 41 interventional studies, 38 across the 4 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
Keenova Therapeutics plc has 4 studies filed under Bursitis — fewer than ten, so there is no comparison to draw.
4 of the studies in Bursitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07278323University of California, San FranciscoFrozen Shoulder and Hormone Replacement Therapy | 2026-12 |
| NCT02283996Massachusetts General HospitalAdhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment | 2026-12 |
| NCT07227662University of Maryland, BaltimoreFeasibility, Usability and Preliminary Efficacy of Home-based FES Fro Adhesive Capsulitis | 2026-12-01 |
| NCT07497737University Hospitals Cleveland Medical CenterOMT for Adhesive Capsulitis | 2027-04-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Bursitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of EN3835 for the treatment of adhesive capsulitis of the shoulder (frozen shoulder).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has received treatment for adhesive capsulitis (in the timeframes outlined below) or is planning to receive any treatment (other than study treatment) for adhesive capsulitis at any time during the study in the affected shoulder, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EN3835 up to 1.74 mg
Drug: EN3835
Placebo
Drug: Placebo
Collagenase clostridium histolyticum
Placebo comparator
Change From Baseline in the Adapted American Shoulder and Elbow Surgeons Shoulder Assessment Form (ASES) Composite Score for the Affected Shoulder at Day 95
Adapted ASES is a self-administered participant reported outcome measure, divided into 2 sections: pain and function. Pain subscale is a single item, 11-point numeric rating scale, ranging from 0 (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying total score for 10 items by 5 and then dividing it by 3, score range of 0 (no function) to 50 (full function). Adapted ASES composite score is the sum of the pain subscale score (50% of the composite score) and function subscale score (50% of the composite score), score range of 0 (worst pain) to 100 (least pain). Positive change from Baseline score means an improvement in pain and/or shoulder function.
Time frame: Baseline, Day 95
Change From Baseline in Passive Range of Motion (PROM) for Forward Flexion in the Affected Shoulder
PROM for forward flexion was measured using a goniometer. Positive change from Baseline means an improvement.
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in PROM for Internal Rotation in the Affected Shoulder
PROM for internal rotation was measured using a goniometer and a spinal level. Positive change from Baseline means an improvement.
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in PROM for External Rotation in the Affected Shoulder
PROM for external rotation was measured using a goniometer. Positive change from Baseline means an improvement.
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in PROM for Abduction in the Affected Shoulder
PROM for abduction was measured using a goniometer. Positive change from Baseline means an improvement.
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in PROM for Shoulder Extension in the Affected Shoulder
PROM for shoulder extension was measured using a goniometer. Positive change from Baseline means an improvement.
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in PROM for Forward Flexion in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
PROM for forward flexion was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in PROM for Internal Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
PROM for internal rotation was measured using a goniometer and a spinal level. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in PROM for External Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
PROM for external rotation was measured using a goniometer PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in PROM for Abduction in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
PROM for abduction was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in PROM for Shoulder Extension in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
PROM for shoulder extension was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in Active Range of Motion (AROM) for Forward Flexion in the Affected Shoulder
AROM for forward flexion was measured using a goniometer. Positive change from Baseline means an improvement.
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in AROM for Internal Rotation in the Affected Shoulder
AROM for internal rotation was measured using a goniometer and a spinal level. Positive change from Baseline means an improvement.
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in AROM for External Rotation in the Affected Shoulder
AROM for external rotation was measured using a goniometer. Positive change from Baseline means an improvement.
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in AROM for Abduction in the Affected Shoulder
AROM for abduction was measured using a goniometer. Positive change from Baseline means an improvement.
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in AROM for Shoulder Extension in the Affected Shoulder
AROM for shoulder extension was measured using a goniometer. Positive change from Baseline means an improvement.
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in AROM for Forward Flexion in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
AROM for forward flexion was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in AROM for Internal Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
AROM for internal rotation was measured using a goniometer and a spinal level. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in AROM for External Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
AROM for external rotation was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in AROM for Abduction in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
AROM for abduction was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in AROM for Shoulder Extension in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline
AROM for shoulder extension was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
Time frame: Baseline, Days 22, 43, 64, and 95
Change From Baseline in the Adapted ASES Composite Score
The adapted ASES is a self-administered participant reported outcome measure, divided into 2 sections: pain and function. Pain subscale is a single item, 11-point numeric rating scale, ranging from (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying the total score for 10 items by 5 and then dividing it by 3, score ranging from 0 (no function) to 50 (full function). The adapted ASES composite score is the sum of the pain subscale score (50% of the composite score) and function subscale score (50% of the composite score). The range for composite score is 0 (worst pain) to 100 (least pain). Positive change from Baseline score means an improvement in pain and/or shoulder function.
Time frame: Baseline, Day 22, 43, and 64
Change From Baseline in the Adapted ASES Function Subscale Score
The adapted ASES function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying the total score for 10 items by 5 and then dividing it by 3, score ranging from 0 (worst no function) to 50 (full function). Positive change from Baseline score means an improvement in shoulder function.
Time frame: Baseline, Day 22, 43, 64, and 95
Change From Baseline in the Adapted ASES Pain Subscale Score
The adapted ASES pain subscale is a single item, 11-point numeric rating scale, ranging from (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Positive change from Baseline score means an improvement in shoulder pain.
Time frame: Baseline, Day 22, 43, 64, and 95
Change From Baseline in the Pain Upon Movement (PUM) Scale Score for the Affected Shoulder
The PUM scale is a single item 11-point numerical rating scale of pain in the affected shoulder after AROM forward flexion, internal rotation, external rotation, abduction, and shoulder extension on a scale from 0 (no pain at all) to 10 (pain as bad as it can be). A decrease from Baseline indicates improvement.
Time frame: Baseline, Days 64 and 95
Change From Baseline in Patient-reported Global Severity of Adhesive Capsulitis Scale
The Patient-reported Global Severity of Adhesive Capsulitis is a single item, 11-point numerical rating scale that asks participants to rate the overall severity of their adhesive capsulitis symptoms on a scale from 0 (no severity) to 10 (severe as can be). A decrease from Baseline indicates improvement.
Time frame: Baseline, Day 22, 43, 64, and 95
Patient-reported Change in Severity of Adhesive Capsulitis Scale
The Patient-reported Change in Severity of Adhesive Capsulitis is a questionnaire that asks participants if their adhesive capsulitis symptoms are "Better, About the Same, or Worse" since the last time the questionnaire was administered. Participants who reported that their symptoms are better or worse are then asked to rate the change in their symptoms on a 7-point ordinal scale for worse and better severity. An overall severity of worse was rated from 0 (almost the same, hardly worse at all) to -6 (a very great deal worse). An overall severity of better was rated from 0 (almost the same, hardly better at all) to 6 (a very great deal better). Only participants with a response of 'Worse' or 'Better' were analyzed. Participants with an overall severity response of 'About the same' were excluded from the summary table below. For overall worse severity, a lower score indicated a worse outcome. For overall better severity, a higher score indicated a better outcome.
Time frame: Days 22, 43, 64 and 95
Number of Responders Assessed With Investigator Assessment of Improvement
Investigator assessment of improvement with treatment in the severity of the participant's treated shoulder using a 7-point Likert scale from very much worse (-3) to very much improved (3). A responder was defined as a response of "very much improved", "much improved" or "minimally improved" in the investigator assessment of improvement with treatment.
Time frame: Days 64 and 95
Number of Responders Assessed by the Subject Satisfaction With Treatment Assessment
Participants rated their satisfaction with treatment on a 7-point Likert scale from very dissatisfied (-3) to very satisfied (3) at specified times for relief of pain in treated shoulder, relief of stiffness in treated shoulder, relief of pain in treated shoulder compared to better shoulder, and relief of stiffness in treated shoulder compared to better shoulder. A responder was defined as a participant with a response of "very satisfied", "satisfied" or "somewhat satisfied" in the satisfaction with treatment.
Time frame: Days 64 and 95
Number of Participants Positive for Anti-AUX-I and Anti-AUX-II Antibodies
Serum samples were collected and tested for the presence of anti-AUX-I and anti-AUX-II antibodies.
Time frame: Day 95
Number of Participants Positive for Neutralizing Antibodies
Serum samples were collected and tested for the presence of anti-AUX-I and anti-AUX-II antibodies. Only samples positive for anti-AUX-I and anti-AUX-II antibodies were analyzed for neutralizing antibodies.
Time frame: Day 95
| Milestone | EN3835 | Placebo |
|---|---|---|
| Started | 102 | 96 |
| Received at least 1 dose of study drug | 101 | 94 |
| Completed | 84 | 80 |
| Not completed | 18 | 16 |
| Withdrew: Adverse event | 6 | 2 |
| Withdrew: Withdrawal by subject | 7 | 6 |
| Withdrew: Lost to follow-up | 3 | 5 |
| Withdrew: Not treated | 1 | 2 |
| Withdrew: Other than specified | 1 | 1 |
Adapted ASES is a self-administered participant reported outcome measure, divided into 2 sections: pain and function. Pain subscale is a single item, 11-point numeric rating scale, ranging from 0 (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying total score for 10 items by 5 and then dividing it by 3, score range of 0 (no function) to 50 (full function). Adapted ASES composite score is the sum of the pain subscale score (50% of the composite score) and function subscale score (50% of the composite score), score range of 0 (worst pain) to 100 (least pain). Positive change from Baseline score means an improvement in pain and/or shoulder function.
| score on a scale | EN3835 | Placebo |
|---|---|---|
| Change From Baseline in the Adapted American Shoulder and Elbow Surgeons Shoulder Assessment Form (ASES) Composite Score for the Affected Shoulder at Day 95 | 41.35 ± 22.432 | 41.16 ± 21.942 |
PROM for forward flexion was measured using a goniometer. Positive change from Baseline means an improvement.
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | 19.1 ± 24.88 | 13.9 ± 22.40 |
| Day 43 | 25.6 ± 26.89 | 21.4 ± 20.14 |
| Day 64 | 31.4 ± 26.31 | 27.3 ± 23.68 |
| Day 95 | 32.8 ± 25.59 | 29.7 ± 27.08 |
PROM for internal rotation was measured using a goniometer and a spinal level. Positive change from Baseline means an improvement.
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | 6.9 ± 23.95 | 7.0 ± 17.94 |
| Day 43 | 11.0 ± 25.97 | 12.4 ± 19.92 |
| Day 64 | 18.0 ± 24.65 | 18.3 ± 21.95 |
| Day 95 | 19.9 ± 22.59 | 21.6 ± 23.11 |
PROM for external rotation was measured using a goniometer. Positive change from Baseline means an improvement.
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | 7.3 ± 19.39 | 8.8 ± 15.61 |
| Day 43 | 11.2 ± 20.98 | 14.5 ± 18.87 |
| Day 64 | 17.4 ± 24.87 | 17.8 ± 17.87 |
| Day 95 | 19.1 ± 21.24 | 19.2 ± 18.20 |
PROM for abduction was measured using a goniometer. Positive change from Baseline means an improvement.
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | 15.6 ± 28.47 | 13.1 ± 23.89 |
| Day 43 | 29.6 ± 30.19 | 18.9 ± 27.13 |
| Day 64 | 35.6 ± 36.76 | 31.1 ± 29.27 |
| Day 95 | 42.1 ± 38.17 | 36.0 ± 33.35 |
PROM for shoulder extension was measured using a goniometer. Positive change from Baseline means an improvement.
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | 3.9 ± 16.51 | 5.7 ± 13.54 |
| Day 43 | 8.0 ± 18.34 | 9.2 ± 16.93 |
| Day 64 | 15.2 ± 18.44 | 12.0 ± 17.23 |
| Day 95 | 20.3 ± 18.30 | 14.7 ± 17.15 |
PROM for forward flexion was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | -34.48 ± 29.067 | -37.33 ± 27.179 |
| Day 43 | -28.34 ± 27.939 | -30.24 ± 26.369 |
| Day 64 | -22.14 ± 27.983 | -23.01 ± 24.200 |
| Day 95 | -20.82 ± 26.245 | -21.06 ± 25.198 |
PROM for internal rotation was measured using a goniometer and a spinal level. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | -30.76 ± 24.692 | -28.51 ± 24.930 |
| Day 43 | -26.81 ± 24.950 | -22.03 ± 24.311 |
| Day 64 | -20.50 ± 21.561 | -16.88 ± 24.096 |
| Day 95 | -18.22 ± 21.444 | -13.49 ± 26.037 |
PROM for external rotation was measured using a goniometer PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | -35.12 ± 22.928 | -35.49 ± 23.027 |
| Day 43 | -31.30 ± 25.102 | -29.40 ± 25.727 |
| Day 64 | -24.46 ± 26.063 | -26.08 ± 24.494 |
| Day 95 | -22.94 ± 22.153 | -25.06 ± 23.844 |
PROM for abduction was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | -54.90 ± 40.162 | -57.56 ± 35.565 |
| Day 43 | -41.37 ± 39.918 | -53.17 ± 36.106 |
| Day 64 | -34.87 ± 39.860 | -41.48 ± 37.136 |
| Day 95 | -28.91 ± 41.483 | -36.54 ± 41.288 |
PROM for shoulder extension was measured using a goniometer. PROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. PROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | -18.82 ± 21.558 | -17.11 ± 19.106 |
| Day 43 | -14.99 ± 22.313 | -14.01 ± 20.363 |
| Day 64 | -7.97 ± 22.633 | -9.91 ± 18.869 |
| Day 95 | -2.87 ± 20.756 | -7.33 ± 17.676 |
AROM for forward flexion was measured using a goniometer. Positive change from Baseline means an improvement.
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | 13.6 ± 26.28 | 13.0 ± 26.55 |
| Day 43 | 21.9 ± 30.00 | 22.3 ± 26.17 |
| Day 64 | 27.7 ± 25.47 | 29.6 ± 28.85 |
| Day 95 | 31.7 ± 25.31 | 30.1 ± 31.20 |
AROM for internal rotation was measured using a goniometer and a spinal level. Positive change from Baseline means an improvement.
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | 7.5 ± 20.45 | 5.8 ± 19.12 |
| Day 43 | 9.1 ± 22.13 | 10.2 ± 20.40 |
| Day 64 | 18.4 ± 22.44 | 17.5 ± 21.55 |
| Day 95 | 19.6 ± 21.99 | 21.6 ± 23.87 |
AROM for external rotation was measured using a goniometer. Positive change from Baseline means an improvement.
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | 5.3 ± 16.85 | 5.6 ± 14.79 |
| Day 43 | 8.7 ± 19.59 | 10.0 ± 19.12 |
| Day 64 | 13.9 ± 22.18 | 15.4 ± 21.65 |
| Day 95 | 16.8 ± 21.67 | 16.1 ± 21.00 |
AROM for abduction was measured using a goniometer. Positive change from Baseline means an improvement.
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | 14.2 ± 30.75 | 13.7 ± 23.17 |
| Day 43 | 26.6 ± 37.79 | 22.2 ± 27.93 |
| Day 64 | 37.2 ± 35.60 | 33.3 ± 30.53 |
| Day 95 | 42.0 ± 37.71 | 39.8 ± 31.79 |
AROM for shoulder extension was measured using a goniometer. Positive change from Baseline means an improvement.
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | 7.0 ± 17.37 | 8.5 ± 15.84 |
| Day 43 | 13.7 ± 21.63 | 12.0 ± 16.72 |
| Day 64 | 16.2 ± 19.29 | 15.3 ± 16.70 |
| Day 95 | 19.7 ± 19.91 | 17.3 ± 17.17 |
AROM for forward flexion was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | -38.34 ± 30.007 | -40.72 ± 24.602 |
| Day 43 | -31.00 ± 29.397 | -32.17 ± 24.879 |
| Day 64 | -23.62 ± 29.115 | -23.82 ± 23.083 |
| Day 95 | -19.83 ± 26.729 | -23.39 ± 24.774 |
AROM for internal rotation was measured using a goniometer and a spinal level. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | -30.53 ± 24.699 | -27.94 ± 24.757 |
| Day 43 | -29.78 ± 24.728 | -23.45 ± 24.923 |
| Day 64 | -20.57 ± 23.335 | -16.99 ± 24.708 |
| Day 95 | -19.27 ± 23.646 | -12.66 ± 27.685 |
AROM for external rotation was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | -34.78 ± 25.743 | -35.82 ± 22.666 |
| Day 43 | -31.07 ± 29.543 | -31.23 ± 23.379 |
| Day 64 | -25.31 ± 28.454 | -25.84 ± 26.291 |
| Day 95 | -22.52 ± 26.313 | -25.42 ± 26.075 |
AROM for abduction was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | -58.41 ± 38.888 | -57.28 ± 36.353 |
| Day 43 | -46.14 ± 41.198 | -49.32 ± 34.988 |
| Day 64 | -35.08 ± 36.868 | -39.82 ± 38.397 |
| Day 95 | -30.74 ± 38.227 | -33.01 ± 39.718 |
AROM for shoulder extension was measured using a goniometer. AROM measurements for the contralateral (unaffected) shoulder were taken at Baseline. AROM measurements of the affected shoulder were take at Baseline, Days 22, 43, 64, and 95. Baseline Value = Measurement at Baseline in Affected Shoulder- Measurement at Baseline Contralateral Unaffected Shoulder Change from baseline was calculated as: (Measurement at Visit in Affected Shoulder - Measurement at Baseline Contralateral Shoulder) - Baseline Value
| degrees | EN3835 | Placebo |
|---|---|---|
| Day 22 | -13.65 ± 19.893 | -15.25 ± 21.385 |
| Day 43 | -7.55 ± 20.771 | -11.65 ± 20.674 |
| Day 64 | -4.29 ± 20.214 | -6.94 ± 20.775 |
| Day 95 | -1.00 ± 18.904 | -5.34 ± 20.922 |
The adapted ASES is a self-administered participant reported outcome measure, divided into 2 sections: pain and function. Pain subscale is a single item, 11-point numeric rating scale, ranging from (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying the total score for 10 items by 5 and then dividing it by 3, score ranging from 0 (no function) to 50 (full function). The adapted ASES composite score is the sum of the pain subscale score (50% of the composite score) and function subscale score (50% of the composite score). The range for composite score is 0 (worst pain) to 100 (least pain). Positive change from Baseline score means an improvement in pain and/or shoulder function.
| score on a scale | EN3835 | Placebo |
|---|---|---|
| Day 22 | 14.87 ± 15.684 | 15.96 ± 14.269 |
| Day 43 | 25.15 ± 21.532 | 21.77 ± 18.199 |
| Day 64 | 38.21 ± 22.837 | 34.98 ± 21.222 |
The adapted ASES function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying the total score for 10 items by 5 and then dividing it by 3, score ranging from 0 (worst no function) to 50 (full function). Positive change from Baseline score means an improvement in shoulder function.
| score on a scale | EN3835 | Placebo |
|---|---|---|
| Day 22 | 7.56 ± 8.245 | 7.96 ± 7.388 |
| Day 43 | 12.82 ± 10.365 | 11.77 ± 9.964 |
| Day 64 | 19.60 ± 12.127 | 17.98 ± 11.337 |
| Day 95 | 21.05 ± 11.538 | 20.73 ± 11.823 |
The adapted ASES pain subscale is a single item, 11-point numeric rating scale, ranging from (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Positive change from Baseline score means an improvement in shoulder pain.
| score on a scale | EN3835 | Placebo |
|---|---|---|
| Day 22 | 7.3 ± 9.61 | 8.0 ± 9.49 |
| Day 43 | 12.3 ± 12.73 | 10.0 ± 11.87 |
| Day 64 | 18.6 ± 12.67 | 17.0 ± 12.29 |
| Day 95 | 20.3 ± 13.11 | 20.4 ± 12.28 |
The PUM scale is a single item 11-point numerical rating scale of pain in the affected shoulder after AROM forward flexion, internal rotation, external rotation, abduction, and shoulder extension on a scale from 0 (no pain at all) to 10 (pain as bad as it can be). A decrease from Baseline indicates improvement.
| score on a scale | EN3835 | Placebo |
|---|---|---|
| Day 64 | -3.6 ± 2.60 | -3.0 ± 2.72 |
| Day 95 | -4.1 ± 2.59 | -3.8 ± 2.96 |
The Patient-reported Global Severity of Adhesive Capsulitis is a single item, 11-point numerical rating scale that asks participants to rate the overall severity of their adhesive capsulitis symptoms on a scale from 0 (no severity) to 10 (severe as can be). A decrease from Baseline indicates improvement.
| score on a scale | EN3835 | Placebo |
|---|---|---|
| Day 22 | -1.8 ± 1.84 | -1.5 ± 1.87 |
| Day 43 | -3.0 ± 2.21 | -2.3 ± 2.16 |
| Day 64 | -4.0 ± 2.41 | -3.6 ± 2.61 |
| Day 95 | -4.4 ± 2.48 | -4.0 ± 2.87 |
The Patient-reported Change in Severity of Adhesive Capsulitis is a questionnaire that asks participants if their adhesive capsulitis symptoms are "Better, About the Same, or Worse" since the last time the questionnaire was administered. Participants who reported that their symptoms are better or worse are then asked to rate the change in their symptoms on a 7-point ordinal scale for worse and better severity. An overall severity of worse was rated from 0 (almost the same, hardly worse at all) to -6 (a very great deal worse). An overall severity of better was rated from 0 (almost the same, hardly better at all) to 6 (a very great deal better). Only participants with a response of 'Worse' or 'Better' were analyzed. Participants with an overall severity response of 'About the same' were excluded from the summary table below. For overall worse severity, a lower score indicated a worse outcome. For overall better severity, a higher score indicated a better outcome.
| score on a scale | EN3835 | Placebo |
|---|---|---|
| Day 22: Worse Severity | -3.4 ± 1.52 | -3.2 ± 2.23 |
| Day 22: Better Severity | 2.4 ± 1.40 | 2.5 ± 1.29 |
| Day 43: Worse Severity | -3.3 ± 1.53 | -4.0 ± 2.16 |
| Day 43: Better Severity | 3.4 ± 1.46 | 3.6 ± 1.44 |
| Day 64: Worse Severity | — | -4.8 ± 0.50 |
| Day 64: Better Severity | 4.5 ± 1.29 | 4.2 ± 1.40 |
| Day 95: Worse Severity | — | -3.5 ± 1.91 |
| Day 95: Better Severity | 4.7 ± 1.27 | 4.7 ± 1.09 |
Investigator assessment of improvement with treatment in the severity of the participant's treated shoulder using a 7-point Likert scale from very much worse (-3) to very much improved (3). A responder was defined as a response of "very much improved", "much improved" or "minimally improved" in the investigator assessment of improvement with treatment.
| Participants | EN3835 | Placebo |
|---|---|---|
| Day 64 | 71 | 59 |
| Day 95 | 80 | 65 |
Participants rated their satisfaction with treatment on a 7-point Likert scale from very dissatisfied (-3) to very satisfied (3) at specified times for relief of pain in treated shoulder, relief of stiffness in treated shoulder, relief of pain in treated shoulder compared to better shoulder, and relief of stiffness in treated shoulder compared to better shoulder. A responder was defined as a participant with a response of "very satisfied", "satisfied" or "somewhat satisfied" in the satisfaction with treatment.
| Participants | EN3835 | Placebo |
|---|---|---|
| Day 64: Pain relief in treated shoulder | 80 | 60 |
| Day 64: Stiffness relief in treated shoulder | 74 | 59 |
| Day 64: Pain relief in treated shoulder compared to better shoulder | 74 | 57 |
| Day 64: Stiffness relief in treated shoulder compared to better shoulder | 73 | 54 |
| Day 95: Pain relief in treated shoulder | 73 | 69 |
| Day 95: Stiffness relief in treated shoulder | 71 | 69 |
| Day 95: Pain relief in treated shoulder compared to better shoulder | 71 | 68 |
| Day 95: Stiffness relief in treated shoulder compared to better shoulder | 68 | 65 |
Serum samples were collected and tested for the presence of anti-AUX-I and anti-AUX-II antibodies.
| Participants | EN3835 | Placebo |
|---|---|---|
| Anti-AUX-I Antibodies | 83 | 3 |
| Anti-AUX-II Antibodies | 81 | 3 |
Serum samples were collected and tested for the presence of anti-AUX-I and anti-AUX-II antibodies. Only samples positive for anti-AUX-I and anti-AUX-II antibodies were analyzed for neutralizing antibodies.
| Participants | EN3835 | Placebo |
|---|---|---|
| Neutralizing AUX-I Antibodies | 31 | 0 |
| Neutralizing AUX-II Antibodies | 4 | 0 |
Collected over Day 1 (after dosing) through Day 95. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EN3835 | 0/101 (0%) | 1/101 (1%) | 69/101 (68.3%) |
| Placebo | 0/94 (0%) | 1/94 (1.1%) | 22/94 (23.4%) |
| Event | EN3835 | Placebo |
|---|---|---|
| FallInjury, poisoning and procedural complications | 0/101 | 1/94 |
| DepressionPsychiatric disorders | 1/101 | 0/94 |
| Event | EN3835 | Placebo |
|---|---|---|
| Injection site bruisingGeneral disorders | 47/101 | 4/94 |
| Injection site painGeneral disorders | 23/101 | 10/94 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 23/101 | 12/94 |
| Injection site swellingGeneral disorders | 14/101 | 2/94 |
All randomized participants who received at least 1 injection of study treatment.
| Age, Continuous(years) | EN3835 | Placebo | Total |
|---|---|---|---|
| Mean | 53.76 ± 7.565 | 55.50 ± 7.806 | 54.59 ± 7.712 |
| Sex: Female, Male(Participants) | EN3835 | Placebo | Total |
|---|---|---|---|
| Female | 65 | 66 | 131 |
| Male | 36 | 28 | 64 |
| Race/Ethnicity, Customized(Participants) | EN3835 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 4 | 6 | 10 |
| Black | 12 | 11 | 23 |
| White | 82 | 72 | 154 |
| Other Race | 2 | 2 | 4 |
| Multiple Race | 0 | 1 | 1 |
| Hispanic or Latino | 14 | 16 | 30 |
| Not Hispanic or Latino | 87 | 78 | 165 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
Ran from Jul 2020 to primary completion in Apr 2022, 20 months.
Results were first posted in Sep 2023, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase